Roche showcases new solutions for automated molecular testing
Category: #health  By Shikha Sinha  Date: 2018-06-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Roche showcases new solutions for automated molecular testing

The Swiss multinational Roche in its recent announcement has unveiled that it will be featuring its new test options to automate molecular testing. The company reportedly will also be offering presentations on important microbiology topics encompassing MRSA screening, healthcare IT, molecular HSV testing, automating LDTs, and more from industry experts in its booth at the ASM Microbe 2018 annual conference held in Atlanta.

Sources familiar with the matter revealed that Roche for its full automated molecular testing cobas 6800 and 8800 systems will be introducing its FDA approved CT/NG test. For the record, the test will allow the research labs to combine STI testing with Roche’s viral load tests including cytomegalovirus (CMV), hepatitis B, hepatitis C, and HIV, while significantly reducing the operating time & labor.

For those uninitiated, Roche’s cobas 6800/8800 Systems are designed to offer the fastest time to results with highest throughput, coupled with the lengthiest walk-away time, that has aided lab officials to drive increased workflow efficiencies, while adapting to their continuously changing laboratory testing demands.

At the American Society for Microbiology's annual conference, the Swiss healthcare major will also be highlighting the addition of its cobas Factor II & Factor V test to its list of options for its automated cobas 4800 system. These recently cleared tests will enable laboratory staff to simultaneously assess Factor II & Factor V genetic mutations from a single sample, in turn reducing hands-on time. Sources cite that the addition to the palate will significantly allow labs to consolidate oncology, genomics, and microbiology assessment onto a single platform.

If industry experts are to be believed, Roche has designed a platform that meets the evolving needs of the modern day molecular diagnostics laboratory. These systems are further poised to set new industry standards with practical innovation for automation, throughput, and speed-of-results, that were previously not so protuberant in molecular diagnostics.



About Author

Shikha Sinha

Email: [email protected]   

Shikha Sinha

Shikha currently manages content operations for a series of news and business portals including MSF, Algosonline, and the like. An electrical & electronics engineer by education, she has prior experience in content & technology writing, content marketing, market resea...

Read More

More News By Shikha Sinha

Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
By Shikha Sinha

Altimmune, Inc., a clinical stage biopharma company, has recently confirmed the closing of a formerly announced acquisition of Spitfire Pharma, Inc., including the strong GLP-1/Glucagon receptor co-agonist product cand...

NeurologyLive expands SAP program by partnering with Cleveland Clinic
NeurologyLive expands SAP program by partnering with Cleveland Clinic
By Shikha Sinha

NeurologyLive has reportedly added the Cleveland Clinic to its Strategic Alliance Partnership (SAP) program. Michael J. Hennessy Jr., President of NeurologyLive’s parent company MJH Associates Inc., said in a sta...

Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019
Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019
By Shikha Sinha

Neurocrine Biosciences Inc., along with Voyager Therapeutics Inc., has reportedly announced the Phase 1 results from the VY-AADC trial in eight patients suffering from Parkinson’s disease. Apparently, the patient...